Steris (STE)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$209.44-2.76%
Close 2026-07-08 · 1-day change
Reading STE? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track STE free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading STE? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track STE free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a stable growth opportunity with a focus on revenue and cash flow expansion. The current thesis state is intact, supported by recent strong financial performance and management's clear growth targets.
The market currently reflects a neutral valuation, with STE priced as cheap compared to its peers. There is a slight expectations gap, indicating that the market anticipates modest growth without significant surprises.
Management is on track to achieve its revenue growth and free cash flow targets for fiscal 2027. However, there is a moderate risk of missing earnings, especially given recent trends in the industry.
The thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT. If these companies continue to perform well, it could provide a favorable backdrop for STE. Conversely, any negative guidance from these peers could adversely affect STE's momentum.
Overall, STE's fundamentals appear strong, but the investment thesis is sensitive to sector performance. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The recent earnings miss raises concerns about future revenue growth, and there are worries about guidance moving forward. These factors contribute to a less favorable outlook for the company.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Reaching this growth target is important for management's plan and for investor trust.
Confirms:Q1 fiscal 2027 revenue growth is reported between 7% and 8%.
Disproves:Q1 fiscal 2027 revenue growth is reported below 7%.
Why it matters: Closing this sale will allow STERIS to focus on core markets and reduce debt.
Confirms:The sale of the Dental segment closes in STERIS's first quarter of fiscal 2025.
Disproves:The sale does not close by the expected date due to regulatory delays.
Why it matters: Updates on revenue growth will indicate if STERIS is on track to meet its targets.
Confirms:Revenue growth reaches 7-8% in fiscal 2027 as targeted.
Disproves:Revenue growth falls below 7% in fiscal 2027.
Why it matters: This would indicate STERIS is not on track to meet its growth target for fiscal 2026.
Confirms:Q2 revenue growth reported below 8% year over year.
Disproves:Q2 revenue growth stays at or above 8% year over year.
Why it matters: Free cash flow results will show STERIS's ability to generate cash for growth.
Confirms:Free cash flow reaches $850M in fiscal 2027 as targeted.
Disproves:Free cash flow falls below $700M in fiscal 2027.
Why it matters: Achieving this target shows Steris is on track with its growth plans. It signals strong demand and effective operations.
Confirms:Q4 revenue growth reaches 8% or more year over year.
Disproves:Q4 revenue growth falls below 5% year over year.
Why it matters: Spending more than this amount may show financial problems or poor resource use.
Confirms:Capital spending is over $375M.
Disproves:Capital spending is at or below $375M.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Changes in leadership can change company plans and affect investor trust. It is important to watch this.
Confirms one read:New leaders say positive things about future plans and growth.
Confirms the other:Stakeholders have negative views or doubts about the leadership change.
Why it matters: The outlook will reflect the impact of the Dental segment divestiture on future growth.
Confirms one read:Management thinks they will do well in fiscal 2025. This is after selling part of the business.
Confirms the other:Management is careful about fiscal 2025. They see some challenges ahead.
Why it matters: This could indicate a broader slowdown in the healthcare sector affecting STERIS.
Confirms:Healthcare sector revenue growth reported below its median.
Disproves:Healthcare sector revenue growth remains at or above its median.
Why it matters: Leadership changes can impact strategy and performance. Clarity on the new CEO's vision is crucial.
Confirms one read:The new CEO outlines a clear strategy and goals within the next quarter.
Confirms the other:There is still uncertainty about the new CEO's plans.
Why it matters: This outlook will reflect the impact of the Dental segment sale on future earnings.
Confirms one read:Management provides a revenue outlook that shows growth in core markets.
Confirms the other:Management gives a revenue outlook that shows a drop or no change.